Olema Pharmaceuticals shares declined 15.1% after AstraZeneca SERENA-4 trial results. AstraZeneca SERENA-4 trial results triggered immediate 15.1% share price drop for Olema.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | 4 | 4 | — | 1 | — | — | — | 1 | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | ‡‡‡ |
|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 261.81 | 434.09 | 505.44 | 461.07 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 266.51 | 438.47 | 515.45 | 469.88 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.70 | 4.46 | 9.25 | 1.67 |
| ST’ Debt | — | — | — | — |
| Other | 17.94 | 36.13 | 41.43 | 50.69 |
| 21.62 | 41.76 | 51.80 | 53.01 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (45.99) | (45.90) | — | — |
—
|
| ’25 | (43.98) | (29.88) | (34.53) | (38.33) |
(146.72)
|
| ’24 | (23.50) | (27.55) | (27.02) | (26.28) |
(104.35)
|
| ’23 | (20.39) | (22.12) | (22.74) | (18.48) |
(83.73)
|
| ’22 | (17.90) | (26.46) | (17.99) | (19.71) |
(82.06)
|
| ’21 | (11.08) | (8.90) | (12.10) | (18.60) |
(50.69)
|
| ’20 | (2.14) | (1.18) | (7.54) | (9.01) |
(19.87)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (45.99) | (46.12) | — | — |
—
|
| ’25 | (43.98) | (29.88) | (34.53) | (38.33) |
(146.72)
|
| ’24 | (23.65) | (27.56) | (27.02) | (26.28) |
(104.51)
|
| ’23 | (20.39) | (22.12) | (22.73) | (18.48) |
(83.71)
|
| ’22 | (17.93) | (26.48) | (18.13) | (19.88) |
(82.43)
|
| ’21 | (11.50) | (9.26) | (12.19) | (19.30) |
(52.26)
|
| ’20 | (2.14) | (1.19) | (7.53) | (9.06) |
(19.92)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.52) | (0.61) | — | — |
—
|
| ’25 | (0.36) | (0.51) | (0.49) | (0.50) |
(1.87)
|
| ’24 | (0.56) | (0.54) | (0.60) | (0.51) |
(2.20)
|
| ’23 | (0.70) | (0.49) | (0.48) | (0.49) |
(2.14)
|
| ’22 | (0.58) | (0.82) | (0.57) | (0.65) |
(2.62)
|
| ’21 | (0.39) | (0.42) | (0.45) | (0.54) |
(1.80)
|
| ’20 | (0.04) | (0.06) | — | (0.50) |
(3.42)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | 2.00 | 2.45 | 5.56 | 2.86 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.68 | 17.79 | 16.78 | 36.26 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 86 | 74 | 96 | 131 | — | — | — |
Employees
|
| — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (104.79) | (96.65) | (129.47) | (162.45) | ‡‡‡‡‡ | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (104.79) | (96.65) | (129.47) | (162.45) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.36 | 0.38 | 0.39 | 0.49 | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | (2.62) | (2.14) | (2.20) | (1.87) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.05) | (1.85) | (1.78) | (1.69) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.06) | (1.85) | (1.78) | (1.69) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.94 | 5.61 | 6.96 | 5.50 | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 40.00 | 45.25 | 58.74 | 87.01 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (82.06) | (83.73) | (104.35) | (146.72) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.36) | 0.01 | (0.16) | — | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (82.43) | (83.71) | (104.51) | (146.72) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 192.35 | 244.89 | 396.72 | 463.65 | — | — | — |
Working Cap'
|
| — | — | — | — | — | ‡‡‡‡‡ | 2.57 | — | — | 3.00 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (201.86) | (261.81) | (434.09) | (502.44) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 197.55 | 253.90 | 408.96 | 478.56 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (40.97%) | (39.24%) | (35.57%) | (33.00%) | ‡‡‡‡‡ | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (43.47%) | (42.82%) | (39.07%) | (36.61%) | ‡‡‡‡‡ | — | — |
ROE
|
Olema Pharmaceuticals (OLMA), a clinical-stage biotech targeting hormone receptor-positive breast cancer with its lead PROTAC degrader palazestrant, has rebounded sharply from 2022 lows of ~$2 to recent breakouts above $20—a 700-800% recovery fueled by Phase 3 trial initiations (OPERA-01/02) and a cash fortress growing 62% to $397M in 2024, providing 20+ quarters of runway at current ~$105M annual burn. Despite pre-revenue status and widening losses (net income -480% to -$129M), per-share efficiency improves (EPS from -$3.42 to -$2.20), book value rises 41% to $6.96/share, and minimal dilution ahead (shares steady at ~79M projected) signal resilience in a sector where 90% of peers falter.
Revenue inflection looms large: analyst forecasts project $2.25M in 2025-2026 ramping 1,100% to $27.9M in 2027, de-risking the model amid superior PFS data in ESR1-mutant trials and a $50B+ addressable market. Forward EV/Sales compresses from 713x to 58x by 2027, with breakeven eyed for 2028-2029, positioning OLMA for partnerships or M&A akin to Seagen’s $43B deal.
Wall Street consensus screams undervaluation: mean price target implies 97% upside (high 166%), correlating with trial catalysts and FDA oncology tailwinds, while routine insider profit-taking post-rally retains significant skin-in-the-game. Risks like 20-30% trial failure rates persist, but quantitative momentum—cash builds, revenue CAGR, and historical price-trial correlations—points to 3-5x potential by commercialization.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.